S&P Futures
4,611.25 -43.50 (-0.93%) Dow Futures
35,579.00 -217.00 (-0.61%) Nasdaq Futures
15,354.25 -241.50 (-1.55%) Russell 2000 Futures
2,137.30 -20.40 (-0.95%) Crude Oil
85.17 +1.35 (+1.61%) Gold
1,813.70 -2.80 (-0.15%)
Kinnate Biopharma Inc. (KNTE)
After hours:
Chart Events
Performance Outlook
| Previous Close | 14.66 |
| Open | 14.61 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's Range | 14.40 - 15.54 |
| 52 Week Range | 14.24 - 41.00 |
| Volume | |
| Avg. Volume | 96,525 |
| Market Cap | 678.6M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.11 |
| Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 47.50 |
- GlobeNewswire
Kinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 Milestones
Announces proof-of-concept preclinical data demonstrating activity of KIN-2787 in NRAS-mutant melanoma Provides update on ongoing KN-8701 trial with expansion to include patients with NRAS-mutant melanoma in monotherapy and initiation of a combination portion with binimetinib planned for first half of 2022 Announces planned initiation of Phase 1 trial of KIN-3248 for first half of 2022 subject to IND clearance by the FDA Updated cash, cash equivalents and investments of approximately $324.9 mill
- GuruFocus.com
Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...
Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells Seagen Inc, Amarin Corp PLC, Therapeutics Acquisition Corp, , Agenus Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Boxer Capital, Llc.
- GlobeNewswire
Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor Candidate Programs at Upcoming Scientific Meetings
AACR Special Conference: Targeting RAS presentation will highlight findings from real-world clinico-genomic study collaboration with Tempus investigating prevalence of Class II and Class III BRAF mutation-positive (BRAF+) solid tumors ASCO GI Cancers Symposium presentation will highlight results from preclinical studies evaluating the company’s lead Fibroblast Growth Factor Receptor (FGFR) inhibitor candidate, KIN-3248 SAN FRANCISCO and SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopha
